Novartis-MIT Center for Continuous Manufacturing



The text that follows is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

About Us

The Novartis-MIT Center for Continuous Manufacturing is a 10-year research collaboration aimed at transforming pharmaceutical production. Combining the industrial expertise of Novartis with MIT’s scientific and technological leadership, the Center develops new technologies to replace the pharmaceutical industry’s conventional batch-based system with a continuous manufacturing process. Continuous manufacturing will benefit patients, healthcare providers, and the pharmaceutical industry by:

  • Accelerating the introduction of new drugs through efficient production processes
  • Requiring the use of smaller production facilities with lower building and capital costs
  • Minimizing waste, energy consumption, and raw material use
  • Monitoring drug quality on a continuous basis rather than through post-production, batch-based testing
  • Enhancing process reliability and flexibility to respond to market needs

Initial research is conducted primarily through PhD programs at MIT laboratories and involves MIT faculty members, students, postdoctoral fellows, and staff scientists. Novartis then applies the research to industrial-scale projects and pilots new manufacturing processes using its own pharmaceutical products. Novartis has committed its manufacturing and R&D resources and $65 million to the Center over the next 10 years.


No comments yet. Why don’t you start the discussion?

    Leave a Reply

    Your email address will not be published. Required fields are marked *